Meet an Unreasonable Venture
EpiBone
Creating bone tissue from a patient's mesenchymal stem cells in vitro for use in bone grafts.
Notable Achievements
- IND approval by the FDA in July 2023 to go into Ph 1/2 clinical trials with our cartilage product.
- Successful completion of our Ph 1/2 clinical trial of our bone product in August 2023.
- $45.8M of equity funding and $3M in grant funding raised to date.
Currently Operating in Six Regions
Press Mentions
November 12, 2024
EpiBone, Inc. Secures Funding Round Led by Kendall Capital Partners to Accelerate Global Expansion of Clinical Trials - Middle East Business News and Information - mid-east.info
Epibone has successfully secured a funding round led by Kendall Capital Partners, propelling its global expansion of clinical trials. This exciting development marks a significant milestone for...
Read on Middle East Business News and Information - mid-east.info »
June 12, 2024
Rubbing Elbows with the Innovate 100 — A Personal Account
The article recounts a personal experience of attending the Innovate 100 event, highlighting networking opportunities with influential figures in the tech industry. The author shares insights...
Read on NJ Tech Weekly »
June 5, 2024
Global Innovators of Indian Origin (2023)
The blog highlights the achievements of global innovators of Indian origin in 2023. It showcases their groundbreaking contributions in various fields, emphasizing their impact on technology,...
Read more »
October 25, 2023
Behind Nina Tandon — The Big Apple and the Biotech Founder
Nina Tandon, a biotech entrepreneur, shares her journey from growing up in New York City to founding her own company. She discusses the challenges she faced and the importance of diversity in the...
Read on Brown Girl Magazine »
July 24, 2023
EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab
/PRNewswire/ -- EpiBone has received Investigational New Drug (IND) clearance from the FDA to begin testing its lab-grown knee cartilage in humans. The...
Read on PRNewswire »
March 9, 2023
EpiBone, emerging biotech company, is relocating to Jersey City — and bringing nearly 100 jobs | ROI-NJ
EpiBone, an emerging biotechnology company co-founded and run by Nina Marie Tandon, is coming to Jersey City after the Board of the New Jersey Economic Development Authority (NJEDA) approved up to...
Read on ROI-NJ »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on EpiBone and over 398 other ventures working to solve the world's toughest problems.